BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 885 filers reported holding BAXTER INTL INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,484,566 | -18.3% | 145,325 | -1.4% | 0.01% | -14.3% |
| Q2 2023 | $6,713,403 | +232.5% | 147,353 | +196.1% | 0.01% | +250.0% |
| Q1 2023 | $2,018,793 | -18.7% | 49,773 | +2.1% | 0.00% | -33.3% |
| Q4 2022 | $2,483,920 | +0.0% | 48,733 | +5.7% | 0.01% | 0.0% |
| Q3 2022 | $2,483,000 | -20.7% | 46,093 | -5.5% | 0.01% | -14.3% |
| Q2 2022 | $3,133,000 | -35.1% | 48,788 | -21.6% | 0.01% | -30.0% |
| Q1 2022 | $4,827,000 | -47.1% | 62,258 | -41.4% | 0.01% | -41.2% |
| Q4 2021 | $9,121,000 | +105.5% | 106,265 | +92.5% | 0.02% | +88.9% |
| Q3 2021 | $4,439,000 | -18.1% | 55,196 | -18.0% | 0.01% | -18.2% |
| Q2 2021 | $5,417,000 | -2.7% | 67,292 | +1.9% | 0.01% | -8.3% |
| Q1 2021 | $5,570,000 | -12.0% | 66,046 | -16.3% | 0.01% | -14.3% |
| Q4 2020 | $6,329,000 | -21.3% | 78,871 | -21.1% | 0.01% | -30.0% |
| Q3 2020 | $8,039,000 | +15.0% | 99,966 | +23.1% | 0.02% | +5.3% |
| Q2 2020 | $6,992,000 | +38.4% | 81,198 | +30.4% | 0.02% | +11.8% |
| Q1 2020 | $5,053,000 | -14.0% | 62,248 | -11.4% | 0.02% | +6.2% |
| Q4 2019 | $5,873,000 | – | 70,235 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |